{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:54Z","timestamp":1784700414430,"version":"3.55.0"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized lymphoma treatment, yet resistance driven by complex regulatory networks remains a major hurdle. Circular RNAs (circRNAs) have emerged as central signaling hubs that integrate metabolic, inflammatory, and oncogenic cues to fine-tune immune checkpoints such as PD-L1 and CD47 in lymphoma. Here, we systematically dissect the molecular mechanisms by which circRNAs govern immune checkpoints in lymphoma, including nuclear transcriptional control, interactions with RNA-binding proteins (RBPs), competitive endogenous RNA (ceRNA) networks, and micropeptide translation. We differentiate between cell-extrinsic, exosome-mediated reprogramming of the tumor microenvironment and cell-intrinsic circRNA circuits within lymphoma cells spatially. Subtype-specific investigations demonstrate the importance of Epstein-Barr virus (EBV)-encoded circRNAs in immune evasion and the synergistic interactions between 9p24.1 amplification and circRNAs in classical Hodgkin lymphoma (cHL). While therapeutic approaches including antisense oligonucleotides, CRISPR-Cas13, and nanodelivery technologies demonstrate preclinical synergy with ICIs, circulating circRNAs show potential as dynamic indicators for predicting ICI responses. We also critically examine ongoing discussions about the flaws of current model systems, the technological constraints of current validation techniques, and the physiological significance of the ceRNA hypothesis. Positioning circRNAs as multimodal regulatory hubs, this review provides a theoretical framework for developing circRNA-based immunotherapies to overcome resistance in lymphoma.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1877435","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:54:26Z","timestamp":1784699666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CircRNA-mediated regulation of immune checkpoints in lymphoma: a multidimensional network perspective"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingjing","family":"Liu","sequence":"first","affiliation":[{"name":"Hematology Department, Bethune International Peace Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hematology Department, Bethune International Peace Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Wu","sequence":"additional","affiliation":[{"name":"Hematology Department, Bethune International Peace Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Hematology Department, Bethune International Peace Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Li","sequence":"additional","affiliation":[{"name":"Hematology Department, Bethune International Peace Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.853480","article-title":"The role of NcRNAs to regulate immune checkpoints in cancer","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management","volume":"97","author":"Ansell","year":"2022","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00005-x","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283002","article-title":"Results from a phase I trial of pembrolizumab plus vorinostat in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"109","author":"Godfrey","year":"2024","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: Have we found the key to unleash the antitumor immune response","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101206","article-title":"New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine","volume":"67","author":"Zheng","year":"2025","journal-title":"Neoplasia (New York NY)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-0243-y","article-title":"The expanding regulatory mechanisms and cellular functions of circular RNAs","volume":"21","author":"Chen","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature11993","article-title":"Natural RNA circles function as efficient microRNA sponges","volume":"495","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature11928","article-title":"Circular RNAs are a large class of animal RNAs with regulatory potency","volume":"495","author":"Memczak","year":"2013","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2017.02.021","article-title":"Translation of circrnas","volume":"66","author":"Pamudurti","year":"2017","journal-title":"Mol Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000000465","article-title":"Extensive translation of circular RNAs driven by N(6)-methyladenosine","volume":"27","author":"Yang","year":"2017","journal-title":"Cell Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617583","article-title":"The potential regulatory roles of circular RNAs in tumor immunology and immunotherapy","volume":"11","author":"Fang","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/cells14141106","article-title":"Circular RNAs as targets for developing anticancer therapeutics","volume":"14","author":"Jeoung","year":"2025","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102631","article-title":"Circular RNAs in cancer immunology: Immune escape, therapeutic resistance, and nanomedicine synergies","volume":"63","author":"Lv","year":"2026","journal-title":"Transl Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105159","article-title":"Circular RNA-mediated tumor immune escape: Mechanistic architecture and nanomedicine-enabled therapeutic reprogramming","volume":"220","author":"Jiang","year":"2026","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1706393","article-title":"Dual-faced circRNAs: Orchestrating immunosuppression and activation in the lung cancer microenvironment","volume":"13","author":"Li","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-021-01406-7","article-title":"The role of lncRNAs and circRNAs in the PD-1\/PD-L1 pathway in cancer immunotherapy","volume":"20","author":"Jiang","year":"2021","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012534","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020602","article-title":"PD-L1 and tumor-associated macrophages in de novo DLBCL","volume":"3","author":"McCord","year":"2019","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 expression by NF-\u03baB in cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010612","article-title":"Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer","volume":"13","author":"Jeong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41419-024-06945-7","article-title":"PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/cells11050801","article-title":"IFN-\u03b3 induces PD-L1 expression in primed human basophils","volume":"11","author":"Bonam","year":"2022","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm7269","article-title":"Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming","volume":"17","author":"Ma","year":"2025","journal-title":"Sci Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-117","article-title":"MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"14","author":"Kaneko","year":"2025","journal-title":"Trans Lung Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0178-x","article-title":"Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas","volume":"33","author":"Anastasiadou","year":"2019","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01689-6","article-title":"HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer","volume":"40","author":"Liu","year":"2021","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.825284","article-title":"Regulation of intrinsic functions of PD-L1 by post-translational modification in tumors","volume":"12","author":"Nihira","year":"2022","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1186\/s12967-026-08200-3","article-title":"METTL3-dependent m(6)A-modified circ_0026652 facilitates immune evasion of diffuse large B-cell lymphoma cells by inhibiting CD8(+) T-cell responses","volume":"24","author":"Gao","year":"2026","journal-title":"J Transl Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.029062","article-title":"Underlying mechanisms and clinical potential of circRNAs in glioblastoma","volume":"31","author":"Zhang","year":"2023","journal-title":"Oncol Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: Structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41408-024-01199-0","article-title":"Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed\/refractory angioimmunoblastic T-cell lymphoma","volume":"14","author":"Zhu","year":"2024","journal-title":"Blood Cancer J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18137","article-title":"Checkpoint CD47 expression in classical Hodgkin lymphoma","volume":"197","author":"Gholiha","year":"2022","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological Malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0781","article-title":"CD47 expression defines efficacy of rituximab with CHOP in non-germinal center B-cell (Non-GCB) diffuse large B-cell lymphoma patients (DLBCL), but not in GCB DLBCL","volume":"7","author":"Bouwstra","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxab002","article-title":"CD47 promotes T-cell lymphoma metastasis by up-regulating AKAP13-mediated RhoA activation","volume":"33","author":"Kitai","year":"2021","journal-title":"Int Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114576","article-title":"Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc\/CD47 axis","volume":"188","author":"Ren","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01289","article-title":"Deubiquitinating enzyme: A potential secondary checkpoint of cancer immunity","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adf2223","article-title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells","volume":"9","author":"Dixon","year":"2024","journal-title":"Sci Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6268","article-title":"A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma","volume":"12","author":"Lee","year":"2023","journal-title":"Cancer Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.21037\/atm-22-5815","article-title":"Identification of immune-related genes and development of a prognostic model in mantle cell lymphoma","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann Trans Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s13770-023-00585-2","article-title":"Circ_SPEF2 regulates the balance of Treg cells by regulating miR-16-5p\/BACH2 in lymphoma and participates in the immune response","volume":"20","author":"Zhou","year":"2023","journal-title":"Tissue Eng Regen Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-3266-5_11","article-title":"Regulations on messenger RNA: Wires and nodes","volume":"1248","author":"Brosseau","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41584-023-00980-y","article-title":"Post-transcriptional checkpoints in autoimmunity","volume":"19","author":"Bechara","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-020-01140-w","article-title":"Circular RNAs serve as miRNA sponges in breast cancer","volume":"27","author":"Misir","year":"2020","journal-title":"Breast Cancer (Tokyo Japan)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15402","article-title":"CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a\/b to disinhibit PD-L1","volume":"113","author":"Dong","year":"2022","journal-title":"Cancer Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2021.2023863","article-title":"Circ_0003645 serves as miR-335-5p sponge to promote the biological process of diffuse large B-cell lymphoma by upregulating NFIB","volume":"55","author":"Lin","year":"2022","journal-title":"Autoimmunity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118682","article-title":"Circular RNAs as central regulators of metabolic reprogramming and immune responses in the breast cancer microenvironment: A comprehensive review","volume":"193","author":"Sherafat","year":"2025","journal-title":"Biomed Pharmacotherapy = Biomed Pharmacot"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.949713","article-title":"Circular RNA-related ceRNA network and prognostic signature for patients with oral squamous cell carcinoma","volume":"13","author":"He","year":"2022","journal-title":"Front Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.800537","article-title":"Identification of a novel survival-related circRNA-miRNA-mRNA regulatory network related to immune infiltration in liver hepatocellular carcinoma","volume":"13","author":"Gan","year":"2022","journal-title":"Front Genet"},{"key":"B62","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41540-025-00638-3","article-title":"Machine learning prediction for AML based on 3D genome selected circRNA","volume":"12","author":"Yuan","year":"2026","journal-title":"NPJ Syst Biol Appl"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.03.045","article-title":"Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance","volume":"54","author":"Denzler","year":"2014","journal-title":"Mol Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2890","article-title":"Detecting and characterizing circular RNAs","volume":"32","author":"Jeck","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030733","article-title":"Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types","volume":"7","author":"Salzman","year":"2012","journal-title":"PloS One"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222509110","article-title":"Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments","volume":"110","author":"Ala","year":"2013","journal-title":"PNAS"},{"key":"B67","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.molcel.2026.01.018","article-title":"Global mapping of circRNA-target RNA interactions reveal P-body-mediated translational repression","volume":"86","author":"Li","year":"2026","journal-title":"Mol Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncrna.2023.12.005","article-title":"Circular RNA-mediated miRNA sponge & RNA binding protein in biological modulation of breast cancer","volume":"9","author":"Zhu","year":"2024","journal-title":"Non-coding RNA Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.148019","article-title":"Interactions between circRNA and protein in breast cancer","volume":"895","author":"Yang","year":"2024","journal-title":"Gene"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvab107","article-title":"A circular RNA derived from FAT atypical cadherin 3 promotes lung cancer progression via forming a regulatory loop with oncogenic ELAV like RNA binding protein 1","volume":"171","author":"Jiang","year":"2022","journal-title":"J Biochem"},{"key":"B71","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/10732748211019138","article-title":"The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p\/Reelin mediation of the PI3K\/AKT\/mTOR signaling pathway","volume":"37","author":"Ling","year":"2021","journal-title":"Kaohsiung J Med Sci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molcel.2017.02.017","article-title":"Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis","volume":"66","author":"Legnini","year":"2017","journal-title":"Mol Cell"},{"key":"B73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-024-02124-6","article-title":"Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1","volume":"23","author":"Zang","year":"2024","journal-title":"Mol Cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1038\/s41467-024-46408-3","article-title":"Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides","volume":"15","author":"Ferreira","year":"2024","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","article-title":"Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides","volume":"625","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218459","article-title":"A circRNA neoantigen vaccine elicits potent antitumor immunity and synergizes with checkpoint blockade in melanoma","volume":"648","author":"Wu","year":"2026","journal-title":"Cancer Lett"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215723","article-title":"Cancer-related micropeptides encoded by ncRNAs: Promising drug targets and prognostic biomarkers","volume":"547","author":"Setrerrahmane","year":"2022","journal-title":"Cancer Lett"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/cells9061473","article-title":"The emerging role and promise of circular RNAs in obesity and related metabolic disorders","volume":"9","author":"Zaiou","year":"2020","journal-title":"Cells"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.12.026","article-title":"Circular RNAs as biomarkers and therapeutic targets in cancer","volume":"83","author":"Beilerli","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02377-9","article-title":"Hsa_circ_0121582 inhibits leukemia growth by dampening Wnt\/\u03b2-catenin signaling","volume":"22","author":"Chen","year":"2020","journal-title":"Clin Trans Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Ins Mexico"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.01.001","article-title":"The biology, function, and applications of exosomes in cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113921","article-title":"Exosomal circRNAs: A key factor of tumor angiogenesis and therapeutic intervention","volume":"156","author":"Zhang","year":"2022","journal-title":"Biomed Pharmacotherapy = Biomed Pharmacot"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3390\/cancers15072133","article-title":"EBV and lymphomagenesis","volume":"15","author":"Sausen","year":"2023","journal-title":"Cancers"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.04.009","article-title":"Critical involvement of circular RNAs in virus-associated cancers","volume":"10","author":"Zebardast","year":"2023","journal-title":"Genes Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00321-22","article-title":"Marek's disease virus virulence genes encode circular RNAs","volume":"96","author":"Chasseur","year":"2022","journal-title":"J Virol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s13258-021-01094-z","article-title":"CircRNA_OTUD7A upregulates FOXP1 expression to facilitate the progression of diffuse large B-cell lymphoma via acting as a sponge of miR-431-5p","volume":"43","author":"Liu","year":"2021","journal-title":"Genes Genomics"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01311-4","article-title":"Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials","volume":"36","author":"Dahl","year":"2022","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12935-021-02296-x","article-title":"CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3","volume":"21","author":"Mei","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4950","DOI":"10.3390\/cancers14194950","article-title":"CircKIF4A is a prognostic factor and modulator of natural killer\/T-cell lymphoma progression","volume":"14","author":"He","year":"2022","journal-title":"Cancers"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1997197","article-title":"Circ_0000745 regulates NOTCH1-mediated cell proliferation and apoptosis in pediatric T-cell acute lymphoblastic leukemia through adsorbing miR-193b-3p","volume":"26","author":"Feng","year":"2021","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-021-00504-4","article-title":"Circular RNA circRNA_0000094 sponges microRNA-223-3p and up-regulate F-box and WD repeat domain containing 7 to restrain T cell acute lymphoblastic leukemia progression","volume":"34","author":"Hou","year":"2021","journal-title":"Hum Cell"},{"key":"B93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s11658-025-00712-y","article-title":"CircNF1 modulates the progression and immune evasion of esophageal squamous cell carcinoma through dual regulation of PD-L1","volume":"30","author":"Wang","year":"2025","journal-title":"Cell Mol Biol Lett"},{"key":"B94","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/genes16060634","article-title":"Exploring the prognostic potential of circSCORE in patients with relapsed\/refractory mantle cell lymphoma","volume":"16","author":"Salim","year":"2025","journal-title":"Genes"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.18632\/aging.102122","article-title":"A circular RNA from APC inhibits the proliferation of diffuse large B-cell lymphoma by inactivating Wnt\/\u03b2-catenin signaling via interacting with TET1 and miR-888","volume":"11","author":"Hu","year":"2019","journal-title":"Aging"},{"key":"B96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ncrna11020022","article-title":"Mechanism of action of circRNA\/miRNA network in DLBCL","volume":"11","author":"Golovina","year":"2025","journal-title":"Non-coding RNA"},{"key":"B97","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40164-021-00208-3","article-title":"Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review","volume":"10","author":"Decruyenaere","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.71840","article-title":"Advances in circular RNA and its applications","volume":"19","author":"Zhao","year":"2022","journal-title":"Int J Med Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13059-021-02263-9","article-title":"Optimized RNA-targeting CRISPR\/Cas13d technology outperforms shRNA in identifying functional circRNAs","volume":"22","author":"Zhang","year":"2021","journal-title":"Genome Biol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: Current perspectives","author":"Samaridou","year":"2020","journal-title":"Adv Drug Delivery Rev"},{"key":"B101","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13046-023-02620-5","article-title":"Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-","volume":"42","author":"Zhou","year":"2023","journal-title":"J Exp Clin Cancer Research: CR"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s461289","article-title":"Synergistic immunoregulation: Harnessing circRNAs and piRNAs to amplify PD-1\/PD-L1 inhibition therapy","volume":"19","author":"Han","year":"2024","journal-title":"Int J Nanomed"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.00109","article-title":"Circular RNAs in blood Malignancies","volume":"7","author":"Perez de Acha","year":"2020","journal-title":"Front Mol Biosci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0409-z","article-title":"Expanded identification and characterization of mammalian circular RNAs","volume":"15","author":"Guo","year":"2014","journal-title":"Genome Biol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.7150\/thno.77350","article-title":"Circular RNA cancer vaccines drive immunity in hard-to-treat Malignancies","volume":"12","author":"Li","year":"2022","journal-title":"Theranostics"},{"key":"B106","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J Controlled Release: Off J Controlled Release Soc"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2023.106364","article-title":"Circularized RNA as novel therapeutics in cancer","volume":"156","author":"Pe\u00f1a-Paladines","year":"2023","journal-title":"Int J Biochem Cell Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1877435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:54:28Z","timestamp":1784699668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1877435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":107,"alternative-id":["10.3389\/fimmu.2026.1877435"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1877435","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1877435"}}